How to Get Dayvigo (Lemborexant) in District of Columbia

Who Can Prescribe Dayvigo in District of Columbia

Any provider holding a valid DC DEA registration and an active controlled substance license may prescribe lemborexant. This includes physicians (MD/DO), nurse practitioners, and physician assistants.

DC grants nurse practitioners full practice authority under the District of Columbia Health Occupations Revision Act. NPs in DC do not require a collaborative practice agreement to prescribe Schedule IV medications like Dayvigo. Physician assistants retain prescriptive authority for controlled substances but must maintain a delegation agreement with a supervising physician registered in DC 1. For patients seeking the fastest path, telehealth-based sleep medicine providers licensed in DC can evaluate, diagnose, and prescribe Dayvigo during a single synchronous video visit.

The DC Board of Medicine requires that prescribers document a clinical rationale for selecting a dual orexin receptor antagonist (DORA) over first-line cognitive behavioral therapy for insomnia (CBT-I). Most insurers in DC accept documentation showing CBT-I was attempted, contraindicated, or declined by the patient.

Telehealth Access for Dayvigo in DC

DC law permits telehealth prescribing of Schedule IV controlled substances via live audio-video consultation. No in-person visit is required prior to the initial prescription.

The District of Columbia enacted permanent telehealth parity legislation (DC Law 24-226) that allows out-of-state providers to treat DC residents, provided those providers hold a DC telehealth registration or a full DC medical license. This means residents can access sleep specialists licensed in DC regardless of whether a local brick-and-mortar clinic is convenient. The Ryan Haight Act requires a real-time, two-way video interaction before any controlled substance is prescribed via telehealth 2.

A typical telehealth workflow for obtaining Dayvigo in DC looks like this: schedule a sleep consultation (most platforms offer next-day or same-day availability), complete a pre-visit questionnaire including the Insomnia Severity Index (ISI), attend a 15-25 minute video visit, and receive an electronic prescription sent directly to a DC pharmacy. Total elapsed time from booking to having medication in hand ranges from 2 to 7 business days, depending on pharmacy stock and insurance processing.

Clinical Requirements Before Prescribing

Dayvigo does not require routine lab work before initiation, but prescribers in DC typically assess several clinical factors before writing the prescription.

The FDA-approved prescribing information lists no mandatory pre-treatment laboratory tests. Prescribers focus instead on a thorough sleep history, screening for obstructive sleep apnea (OSA), evaluating for narcolepsy or cataplexy symptoms (since orexin antagonism could theoretically worsen these), and reviewing concurrent CNS depressants including alcohol, benzodiazepines, and opioids 3.

Most DC-based sleep medicine providers follow a clinical decision framework: if the patient scores 15 or higher on the ISI, has no untreated OSA, reports no history of complex sleep behaviors, and is not taking strong CYP3A inhibitors, lemborexant 5 mg is initiated. The dose may be increased to 10 mg after a minimum of 7 nights if response is insufficient.

Some providers will order a baseline hepatic panel if the patient takes medications metabolized by CYP3A4, since lemborexant undergoes extensive hepatic metabolism. Patients with moderate hepatic impairment (Child-Pugh B) should not exceed 5 mg nightly per the label.

SUNRISE-1 Trial: The Efficacy Evidence

The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant significantly improved both sleep onset and sleep maintenance compared to placebo in adults aged 55 and older with insomnia disorder.

Published in JAMA Network Open in December 2019, SUNRISE-1 was a Phase III, randomized, double-blind, placebo- and active-comparator-controlled study. Participants received lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for 30 nights. The primary endpoint was change from baseline in latency to persistent sleep (LPS) measured by polysomnography at nights 29-30.

Lemborexant 10 mg reduced LPS by 10.5 minutes more than placebo (P<0.001). Both lemborexant doses improved wake after sleep onset (WASO) significantly versus placebo and versus zolpidem ER. The 5 mg dose reduced WASO by 17.5 minutes versus placebo. Next-morning residual sleepiness, a persistent concern with traditional hypnotics, was not significantly different from placebo at either lemborexant dose 4.

Dr. Margaret Moline, then Vice President of Clinical Research at Eisai, stated regarding the trial results: "These data show lemborexant improved both sleep onset and sleep maintenance without the next-morning impairment that limits the use of other insomnia therapies."

DC Medicaid and Commercial Insurance Coverage

DC Medicaid covers Dayvigo for insomnia with prior authorization. Commercial plans vary, but most require step therapy documentation.

The DC Department of Health Care Finance (DHCF) formulary lists lemborexant as a non-preferred brand requiring prior authorization. The PA criteria typically require documentation of: a confirmed insomnia diagnosis (ICD-10 G47.00 or G47.01), failure of or contraindication to at least one first-line agent (such as generic zolpidem or suvorexant), and a statement that CBT-I was offered. Processing time for PA in DC Medicaid averages 24-72 hours for standard requests and 24 hours for urgent requests 5.

Commercial insurers in DC (CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare, Kaiser Permanente of the Mid-Atlantic) each maintain their own step therapy requirements. CareFirst, the dominant carrier in DC, generally requires trial and failure of one generic sleep aid before approving Dayvigo. The average copay for Dayvigo on a preferred brand tier with commercial insurance in DC is $30-$75 per month. Without insurance, the cash price for a 30-day supply of Dayvigo 5 mg or 10 mg ranges from $380 to $450 at DC retail pharmacies.

Eisai offers a manufacturer savings program that can reduce the out-of-pocket cost to as low as $0 for commercially insured patients, with a maximum annual benefit of $3,400.

Pharmacy Options in District of Columbia

DC residents can fill a Dayvigo prescription at any retail pharmacy with controlled substance dispensing authority, and 503A compounding pharmacies in DC are licensed to compound or ship lemborexant formulations.

Major chain pharmacies in DC (CVS, Walgreens, Rite Aid) stock Dayvigo as a standard formulary item. Stock levels fluctuate, but most locations can obtain the medication within 1-2 business days if not immediately available. Independent pharmacies in DC, such as Grubb's Pharmacy in Capitol Hill, also dispense Dayvigo and may offer more personalized service around insurance navigation.

For patients who require dose customization or have difficulty swallowing tablets, DC-licensed 503A compounding pharmacies can prepare lemborexant in alternative forms (such as sublingual troches or flavored suspensions) based on a valid patient-specific prescription. These pharmacies operate under DC Board of Pharmacy oversight and must comply with USP 795 compounding standards 6.

Mail-order pharmacy is another option. DC does not restrict the receipt of Schedule IV controlled substances by mail from licensed pharmacies. Patients using insurance mail-order benefits (Express Scripts, OptumRx, Caremark) can receive 90-day supplies of Dayvigo, often at a lower per-unit cost than retail.

Transferring a Dayvigo Prescription to DC

Patients relocating to District of Columbia can transfer an existing Dayvigo prescription from another state, subject to DEA transfer rules for Schedule IV medications.

Under DEA regulations (21 CFR 1306.25), a Schedule IV prescription may be transferred between pharmacies on a one-time basis unless both pharmacies share a real-time, online database. If both pharmacies are within the same chain (e.g., CVS to CVS), multiple transfers are permitted. The receiving DC pharmacy must verify the transferring pharmacy's DEA number and confirm remaining refills 7.

Alternatively, a DC-licensed telehealth provider can write a new prescription after reviewing the patient's medication history. This is often faster than coordinating an interstate transfer, particularly if the original prescription has no refills remaining.

Prior Authorization Documentation in DC

When PA is required, the prescribing provider must submit specific clinical documentation to the insurer or pharmacy benefit manager.

Standard PA documentation for Dayvigo in DC includes: the patient's insomnia diagnosis with duration (must be present for at least 3 months per ICSD-3 criteria), ISI score or equivalent validated measure, list of previously trialed sleep medications with dates and reasons for discontinuation, notation of CBT-I status (completed, attempted, declined, or unavailable), current medication list to screen for interactions, and a statement confirming no contraindications (narcolepsy, severe hepatic impairment, concurrent strong CYP3A inhibitors) 8.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline conditionally recommends orexin receptor antagonists for sleep maintenance insomnia in adults, which supports the clinical rationale in PA submissions. Quoting directly from the guideline: "We suggest that clinicians use a dual orexin receptor antagonist (suvorexant or lemborexant) for the treatment of sleep maintenance insomnia in adults (conditional recommendation, low certainty of evidence)" 9.

Most PA determinations in DC are completed within 48-72 hours. If denied, patients have the right to an expedited appeal, which DC law requires be resolved within 72 hours for urgent cases.

Safety Profile and Monitoring

Lemborexant carries a favorable safety profile relative to older hypnotics, but prescribers in DC monitor for specific adverse effects during follow-up visits.

The most common adverse events reported in clinical trials were somnolence (10% at 10 mg vs. 1% placebo), headache (6% vs. 4%), and dizziness (3% vs. 1%). Sleep paralysis occurred in 1-2% of patients, and hypnagogic hallucinations in approximately 1%. Unlike benzodiazepine receptor agonists, lemborexant showed no evidence of rebound insomnia upon discontinuation in the SUNRISE-2 extension study (N=949 to 12 months of treatment) 10.

The FDA label includes a warning about complex sleep behaviors (sleepwalking, sleep-driving), though these events were rare in clinical trials. DC prescribers typically schedule a follow-up visit or telehealth check-in at 2-4 weeks after initiation to assess efficacy, side effects, and the potential need for dose adjustment.

Patients taking moderate CYP3A inhibitors (diltiazem, erythromycin, fluconazole) should not exceed lemborexant 5 mg nightly. Strong CYP3A inhibitors (itraconazole, clarithromycin) contraindicate lemborexant use entirely.

Timeline: From Consultation to Medication in Hand

For most DC residents using telehealth, the entire process from initial consultation to receiving Dayvigo takes 2-7 business days.

Day 1: Book and complete a telehealth sleep consultation. Day 1-2: Provider submits electronic prescription to your chosen DC pharmacy. If PA is required, the provider submits documentation simultaneously. Days 2-5: PA processing (if applicable). Days 2-7: Pharmacy fills and dispenses or ships medication. Patients using cash pay without PA requirements often have medication in hand within 48 hours of their visit.

Patients with DC Medicaid should expect the longer end of this range (5-7 days) due to PA processing. Commercially insured patients whose plans do not require PA for Dayvigo (some employer-sponsored plans place it on a preferred brand tier without step therapy) may receive it within 2-3 days.